Summit makes a $5B bet on Akenso’s bispecific antibody to be fruitful

December 13, 2022

Sarepta’s DMD Drug Off to a Solid Start But Elevidys Problem Lingers

January 30, 2024

Emergent Sells Travel Vaccine Portfolio to Bavarian Nordic For Over $270M

February 20, 2023

Must Read

Top 10 Data Architecture Challenges in Modern Pharma Organizations

June 19, 2026

The Next Evolution of Decentralized Clinical Trials

June 19, 2026

Despite a mid-stage miss, Mirum and Incyte strengthen the case for approval in uncommon bone disease

June 19, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

Merck Pays $20 Million Upfront to Access Quotient’s Somatic Genomics Platform for IBD Research

Phase 3 Lagoon Trial Misses Survival Goal for Jazz’s Zepzelca in Second-Line Small Cell Lung Cancer

Novartis Reports Positive Phase 1/2 Results for Del-Brax in FSHD

Caribou Gets CAR-T Boost Ahead of Phase 3 Trial

Takeda’s Inhibitor Gets the Better of BMS’ Sotyktu in Phase 3 Psoriasis Battle

Eli Lilly Secures Global Rights to AlzeCure Alzheimer’s Drug Candidate in Deal Worth Over $1 Billion

Ascidian & Lilly Pen RNA Exon Editing Agreement for Genetic Kidney Issues

Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Top 10 Data Architecture Challenges in Modern Pharma Organizations

The Next Evolution of Decentralized Clinical Trials

Is Pharma Ready for the Age of Autonomous Work?

Top 10 Forces Reshaping the Future of Life Sciences Operations

Tag: Pfizer investment in valneva

Pfizer to back Valneva with €91M investment for phase 3 Lyme disease vaccine trial

Editor Picks

Summit makes a $5B bet on Akenso’s bispecific antibody to be fruitful

Sarepta’s DMD Drug Off to a Solid Start But Elevidys Problem Lingers

Emergent Sells Travel Vaccine Portfolio to Bavarian Nordic For Over $270M

Must Read

Top 10 Data Architecture Challenges in Modern Pharma Organizations

The Next Evolution of Decentralized Clinical Trials

Despite a mid-stage miss, Mirum and Incyte strengthen the case for approval in uncommon bone disease

Hot Topics

About Us

Follow Us